Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B. Saad, Jia Wu, Xuetao Lu et al.|The Lancet Digital Health|2023Cited by 108
Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in MelanomaShelly Kalaora, Yardena Samuels, Yochai Wolf et al.|Cancer Discovery|2018Cited by 100
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance statusJoao V. Alessi, Mark M. Awad, Biagio Ricciuti et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 58
ACR Appropriateness Criteria® Thoracic Outlet SyndromeOmar Zurkiya, Karin E. Dill, Suvranu Ganguli et al.|Journal of the American College of Radiology|2020Cited by 37